Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma | Zendy

Sumit Gaur | Zendy; Osvaldo Padilla | Zendy; Zeihleh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

Author(s) -

Sumit Gaur,

Osvaldo Padilla,

Zeihleh

Publication year - 2013

Publication title -

lymphoma

Language(s) - English

Resource type - Journals

eISSN - 2090-3103

pISSN - 2090-309X

DOI - 10.1155/2013/290585

Subject(s) - plasmablastic lymphoma , lymphoma , rituximab , medicine , chemotherapy , large cell , cd20 , b cell , aggressive lymphoma , non hodgkin's lymphoma , oncology , pathology , immunology , antibody , adenocarcinoma , cancer

Cluster designation (CD) 20 antigen is expressed on most B-cell lymphomas and serves as a therapeutic target for rituximab. A small minority of aggressive B-cell lymphomas, predominantly plasmablastic variants, do not express CD 20. We systematically reviewed all cases of aggressive B-cell lymphomas diagnosed at our institution over a period of 13 years. Of the 232 cases, 7 did not express CD 20. Five of these were plasmablastic lymphomas while two were unclassifiable B-cell lymphomas. While most of the plasmablastic lymphomas responded to chemotherapy, patients with unclassifiable lymphomas were primarily refractory or relapsed soon after chemotherapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research